Unigen Publishes Study Results on Attenutin™ as a Promising Herbal Supplement for Respiratory System Support
TACOMA, WASHINGTON – November 14, 2024: Unigen Inc., has published promising results from a study evaluating Attenutin™ as a natural supplement to combat oxidative stress, chronic inflammation, and compromised immune response, particularly in elderly individuals facing respiratory challenges. Attenutin™ is a standardized bioflavonoid composition derived from the roots of Scutellaria baicalensis and the heartwoods of Acacia catechu. Results were published in the Journal of Nutrients special issue Nutritional Epidemiology: The Role of Bioactive Compounds in Human Health and Diseases (2nd Edition).
Oxidative stress and chronic inflammation can create a perpetual cycle, particularly in the elderly, where impaired immune function amplifies susceptibility to oxidative damage and oxidative stress further weakens the immune response. “This cycle is especially detrimental to the respiratory system, which is vulnerable to exogenous attacks during cold and flu seasons or under conditions of heavy air pollution,” explained Dr. Mesfin Yimam, Unigen’s Director of Pre-Clinical Research.
“There has been limited availability of scientifically validated effective natural supplements for respiratory system support,” said Dr. Yimam. This study addresses that gap by evaluating Attenutin™ in preclinical models of oxidative stress-accelerated aging and immunosuppression. Key findings include enhanced immune response to vaccination, increased antioxidant capacity, preservation of immune organs, reduced inflammatory biomarkers, and elevated immunoglobulin levels.
“These results suggest that Attenutin™ offers antioxidative, anti-inflammatory, and immune-regulatory benefits, potentially making it a valuable natural supplement for addressing respiratory conditions associated with aging and oxidative stress,” stated Dr. Yimam.
In addition to these findings, Attenutin™ has previously been evaluated in a human clinical study and was found to be effective in supporting mucosal immunity with strong induction of endogenous antioxidation enzymes in participants challenged with the influenza virus.
Dr. Yimam added, “Discovery and innovation at Unigen are rooted in the endless potential of nature. By capitalizing the power of our diverse plant library, we develop sustainable and effective solutions that promote health and well-being. We strive to bridge the gap between nature and mankind, ensuring that the best of nature is accessible, beneficial, and safe for all.”
Visit the Attenutin™ page for additional information and connect with a Unigen Sales Manager.
Kathy Markham
Marketing Manager
Email: kmarkham@unigen.net
Website: unigen.net
About Unigen, Inc.
Unigen discovers, develops, and manufactures proprietary natural-product active ingredients for dietary supplements, cosmetic and personal care products, prescription medical food and botanical drug products. The Company discovers its ingredients through its high-throughput screening PhytoLogix® approach applied to a proprietary well-annotated collection of botanicals and a legacy mining approach applied to botanicals having known medicinal benefits.
Mechanism of action, safety, and efficacy are documented with extensive preclinical in vitro and by human clinical studies. Unigen protects its discoveries with issued patents and patent filings in all major territories and manufactures its products to GMP standards. Unigen commercializes its proprietary ingredients through licensing and ingredient supply alliances with commercial partners engaged in the manufacture, distribution, and marketing of end-products in each of Unigen’s target markets.
Notice Regarding Forward-Looking Information:
This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.